Nektar Therapeutics

Nektar shows durability of Opdivo combo in 18-month update
Fierce Biotech
Mon, 11/11/19 - 10:53 am
Nektar Therapeutics
NKTR-214
Opdivo
Bristol-Myers Squibb
melanoma
clinical trials
3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting
Motley Fool
Wed, 10/9/19 - 10:25 am
SITC
cancer immunotherapy
Autolus Therapeutics
Mirati Therapeutics
Nektar Therapeutics
This Bristol-Partnered Biotech Stock Just Fumbled On A Cancer Study
Investors Business Daily
Thu, 09/26/19 - 07:39 pm
Bristol-Myers Squibb
Nektar Therapeutics
breast cancer
clinical trials
NKTR-214
Nektar Therapeutics stock drops after results
Marketwatch
Thu, 08/8/19 - 11:39 pm
Nektar Therapeutics
earnings
Nektar takes a hit as the FDA swerves away from opioid reviews — leaving NKTR-181 in limbo
Endpoints
Fri, 07/26/19 - 11:57 am
Nektar Therapeutics
opioids
NKTR-181
FDA
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
Xconomy
Wed, 06/5/19 - 10:43 am
ASCO 2019
cancer
immunotherapy
diagnostics
Veracyte
Grail
Moderna Therapeutics
Amgen
Nektar Therapeutics
Blueprint Medicines
Merck
AstraZeneca
Roche
breast cancer
A tale of two ASCOs: Nektar gains on durability of complete response rate for NKTR-214 combo
BioCentury
Wed, 06/5/19 - 12:12 am
ASCO 2019
NKTR-214
Nektar Therapeutics
metastatic melanoma
What Is Nektar Therapeutics' New Game Plan?
Motley Fool
Sun, 05/26/19 - 11:13 am
Nektar Therapeutics
spinoffs
NKTR-181
non-opioid pain treatments
Nektar Therapeutics launches Inheris Biopharma
Pharmaceutical Business Review
Fri, 05/24/19 - 10:37 am
Nektar Therapeutics
Inheris Biopharma
CNS
In a change of plans, Nektar spins out its opioid into a new biotech subsidiary as FDA PDUFA date looms
Endpoints
Thu, 05/23/19 - 09:52 am
Nektar Therapeutics
spinoffs
NKTR-181
opioids
Inheris Biopharma
Bladder cancer readout sees Nektar shares hit
Fierce Biotech
Tue, 02/12/19 - 11:36 am
Nektar Therapeutics
bladder cancer
NKTR-214
Opdivo
Bristol-Myers Squibb
Here's Why Nektar Therapeutics Surged Today
Motley Fool
Tue, 01/8/19 - 07:12 pm
Nektar Therapeutics
JPMHC 2019
NKTR-214
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214
BioCentury
Tue, 11/6/18 - 11:35 am
Pfizer
Nektar Therapeutics
NKTR-214
Xtandi
Talzenna
Bavencio
prostate cancer
Did Bristol-Myers Squibb Make a Huge Mistake With Nektar?
Motley Fool
Tue, 10/2/18 - 10:13 am
Bristol-Myers Squibb
Nektar Therapeutics
NKTR-2014
Nektar’s long-acting IL-2 NKTR-214 has 'zero value,' claims analyst
Fierce Biotech
Mon, 10/1/18 - 09:42 am
Nektar Therapeutics
NKTR-214
The opioid drug that addicts don't like could be approved next spring
Bizjournals.com
Thu, 08/2/18 - 10:07 am
Nektar Therapeutics
NKTR-181
opioids
opiod crisis
#ASCO18: A Weekend of Surprises
Motley Fool
Sun, 06/3/18 - 09:13 pm
ASCO 2018
Bluebird Bio
Loxo Oncology
Nektar Therapeutics
Celgene
Grail
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Motley Fool
Fri, 05/18/18 - 10:00 pm
ASCO
Endocyte
Loxo Oncology
Blueprint Medicines
Nektar Therapeutics
Jounce Therapeutics
Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors
CP Wire
Wed, 04/11/18 - 09:36 am
Nektar Therapeutics
NKTR-214
NKTR-262
cancer
solid tumors

Pages